[1] | Sett AK, Robinson TG, and Mistri AK. Current status of statin therapy for stroke prevention. Expert Rev Cardiovasc Ther 9 (2011) 1305-14. |
[2] | Swindle JP, Potash J, Kulakodlu M, Kuznik A, and Buikema A. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin. Am J Geriatr Pharmacother 9 (2011) 471-82. |
[3] | Tramontina AC, Wartchow KM, Rodrigues L, Biasibetti R, Quincozes-Santos A, Bobermin L, Tramontina F, and Gonçalves CA. The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats. J Neural Transm 118 (2011) 1641-9. |
[4] | Wang Q, Zengin A, Deng C, Li Y, Newell MKA, Yang GY, Lu Y, Wilder-Smith EP, Zhao H, and Huang XF. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol 216 (2009) 132-8. |
[5] | Zhang X, Tao Y, Troiani L, and Markovic-Plese S. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol 87 (2011) 3431-7. |
[6] | Mok SW, Thelen KM, Riemer C, Bamme T, Gultner S, Lutjohann D, and Baier M. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem Biophys Res Commun 348 (2006) 697-702. |
[7] | Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 1037 (2005) 1-6. |
[8] | Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fiévet C, and Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS 452 (1999) 160-4. |
[9] | Vega GL, Weiner MF, Lipton AM, Von Bergmann K, Lutjohann D, Moore C, and Svetlik D. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 60 (2003) 510-5. |
[10] | Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, Schubert-Zsilavecz M, Karas M, Müller WE, and Wood WG. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 312 (2005) 786-93. |
[11] | Nagy J. The NR2B subtype of NMDA receptor: a potential target for the treatment of alcohol dependence. Curr Drug Targets CNS Neurol Disord 3 (2004) 169-79. |
[12] | Du X, Elberger AJ, Matthews DB, and Hamre KM. Heterozygous deletion of NR1 subunit of the NMDA receptor alters ethanol-related behaviors and regional expression of NR2 subunits in the brain. Neurotoxicol Teratol 34 (2012) 177-86. |
[13] | Ward RJ, Lallemand F, and de Witte P. Biochemical and neurotransmitter changes implicated in alcohol-induced brain damage in chronic or 'binge drinking' alcohol abuse. Alcohol Alcohol 44 (2009) 128-35. |
[14] | McCool BA, Christian DT, Diaz MR, and Läck AK. Glutamate plasticity in the drunken amygdala: the making of an anxious synapse. Int Rev Neurobiol 91 (2010) 205-33. |
[15] | Rubio M, Villain H, Docagne F, Roussel BD, Ramos JA, Vivien D, Fernandez-Ruiz J, and Ali C. Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. PLoS One 6 (2011) e23690. |
[16] | Cole JC, Littleton JM, and Little HJ. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacol 147 (2000) 403-11. |
[17] | File SE, Andrews N, al-Farhan M, and Wu PY. The role of 5-HT in the anxiogenic effects of acute ethanol withdrawal and in the long-lasting cognitive deficits. Alcohol 2 (1993) 495-9. |
[18] | Zhang Z, Morse AC, Koob GF, and Schulteis G. Dose and time-dependent expression of anxiety-like behavior in the elevated plus-maze during withdrawal from acute and repeated intermittent ethanol intoxication in rats. Alcohol Clin Exp Res 31 (2007) 1811-9. |
[19] | Uzbay T, Kayir H, Celik T, and Yüksel N. Acute and chronic tianeptine treatments attenuate ethanol withdrawal syndrome in rats. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 478-85. |
[20] | CL. Anxiety-like behaviors following chronic ethanol exposure. Neurosci Biobehav Rev 28 (2005) 837-50. |
[21] | Pandey SC, Zhang D, Mittal N, and Nayyar D. Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety. J Pharmacol Exp Ther 288 (1999) 866-78. |
[22] | Pellow S, Chopin P, File SE, and Briley M. Validation of open: closed arm entries in the elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14 (1985) 149-67. |
[23] | Prut L, and Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463 (2003) 3-33. |
[24] | Cruz AP, Frei F, and Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49 (1994) 171-6. |
[25] | Rodgers RJ, and Cole JC. An ethological analysis of chlordiazepoxide and bretazenil (Ro16-6028) in the murine elevated plus-maze. Behav Pharmacol 4 (1993) 573- 80. |
[26] | Setem J, Pinheiro AP, Motta VA, Morato S, and Cruz AP. Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze. Pharmacol Biochem Behav 62 (1999) 515-21. |
[27] | Kalueff AV, Wheaton M, and Murphy DL. What´s wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav Brain Res 179 (2007) 1-18. |
[28] | Lister RG. Ethologically-based animal models of anxiety disorders. Pharmacol Ther 46 (1990) 321-40. |
[29] | Kalueff AV, and Tuohimaa P. Grooming analysis algorithm for neurobehavioural stress research. Brain Res Brain Res Protoc 13 (2004) 151-8. |
[30] | Crews FT, Morrow AL, Criswell H, and Breese G. Effects of ethanol on ion channels. Int Rev Neurobiol 39 (1996) 283-367. |
[31] | Guimaraes FS, Carobrez AP, De Aguiar JC, and Graeff FG. Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacol 103 (1991) 91- 4. |
[32] | Gatch MB, and Lal H. Animal models of the anxiogenic effects of ethanol withdrawal. Drug Dev Res 54 (2001) 95-115. |
[33] | Yan J, Xu Y, Zhu C, Zhang L, Wu A, Yang Y, Xiong Z, Deng C, Huang XF, Yenari MA, Yang YG, Ying W, and Wang Q. Simvastatin prevents dopaminergic neurodegeneration in experimental Parkinsonian models: the association with anti-inflammatory responses. PLoS One 6 (2011) e20945. |
[34] | Läck AK, Diaz MR, Chappell A, DuBois DW, and McCool BA. Chronic ethanol and withdrawal differentially modulate pre- and postsynaptic function at glutamatergic synapses in rat basolateral amygdala. J Neurophysiol 98 (2007) 3185-96. |
[35] | Roberto M, Schweitzer P, Madamba SG, Stouffer DG, Parsons LH, and Siggins GR. Acute and chronic ethanol alter glutamatergic transmission in rat central amygdala: an in vitro and in vivo analysis. J Neurosci 24 (2004) 1594-1603. |
[36] | Melendez RI, Vuthiganon J, and Kalivas PW. Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. J Pharmacol Exp Ther 314 (2005) 139-47. |
[37] | Kalivas, P.W. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 10 (2009) 561-72. |
[38] | Blednov YA, and Harris RA. Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int J Neuropsychopharmacol 11 (2008) 775-93. |
[39] | Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L, Adams LJ, Vengeliene V, Spanagel R, Zhang Y, Shen J, George DT, Hommer D, and Heilig M.. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 67 (2010) 1069-77. |
[40] | Littleton, J.M. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med 1 (2007) 115-25. |